Oncotarget · 2016 · 51 citations · 39 references
MedicineImmunologyOncologyCancer ImmunologyHepatologyTumor ImmunologyHepatic PathophysiologyHepatobiliary CancerHepatocellular CarcinomaLiver CancerLiver DiseaseTumor-associated MacrophagesEpithelial-mesenchymal Transition In CancerEpithelial-mesenchymal Transition MarkersHepatic TumorsHepatocellular Carcinoma PathogenesisHepatocellular Carcinoma TreatmentHepatopancreatobiliary SurgeryLiver ImmunologySorafenib Therapy
// Yan-Ru Deng 1, * , Wen-Bin Liu 2, * , Zhe-Xiong Lian 3 , Xingsheng Li 4 , Xin Hou 5 1 Intensive Care Unit, Affiliated Provincial Hospital of Anhui Medical University, Hefei, China 2 Department of Hepatic Surgery and Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Affiliated Provincial Hospital of Anhui Medical University, Hefei, China 3 Liver Immunology Laboratory, Institute of Immunology and School of Life Sciences, University of Science and Technology of China, Hefei, China 4 Department of Gerontology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China 5 Anhui Provincial Laboratory of Microbiology and Parasitology, Department of Microbiology and Parasitology, Anhui Medical University, Hefei, Anhui, China * These authors have contributed equally to this work Correspondence to: Xin Hou, email: houxin45@mail.ustc.edu.cn Xingsheng Li, email: lxs2858@163.com Keywords: hepatocellular carcinoma, epithelial-mesenchymal transition, sorafenib, HGF, Met Received: March 27, 2016 Accepted: May 01, 2016 Published: May 18, 2016 ABSTRACT Tumor-associated macrophages, crucial components of the microenvironment in hepatocellular carcinoma, hamper anti-cancer immune responses. The aim of the present study was to investigate the effect of sorafenib on the formation of the tumor microenvironment, especially the relationship between polarized macrophages and hepatocytes. Macrophage infiltration was reduced in patients with hepatocellular carcinoma who were treated with sorafenib. In vitro , sorafenib abolished polarized macrophage-induced epithelial mesenchymal transition (EMT) and migration of hepatocellular carcinoma cells but not normal hepatocytes. Moreover, sorafenib attenuated HGF secretion in polarized macrophages, and decreased plasma HGF in patients with hepatocellular carcinoma. Additionally, sorafenib abolished the polarized macrophage-induced activation of the HGF receptor Met in hepatocellular carcinoma cells. Our findings suggest that sorafenib inhibits polarized macrophage-induced EMT in hepatocellular carcinoma cells via the HGF-Met signaling pathway. These results contribute to our understanding of the immunological mechanisms that underlie the protective effects of sorafenib in hepatocellular carcinoma therapy.
39
Global Cancer Statistics, 2002
Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2005 · 18.4K citations · Full text
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 13K citations · Full text
Medicine, Oncology, Pharmacology +12
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Sendurai A. Mani, Wenjun Guo, Mai-Jing Liao et al. · Cell · 2008 · 8.7K citations · Full text
Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations
Medicine, Oncology, Pharmacotherapy +11
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Bernard Escudier, Tim Eisen, Walter M. Stadler et al. · New England Journal of Medicine · 2007 · 4.8K citations · Full text
Medicine, Nephrology, Oncology +11